2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…2020 American Transplant Congress
Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation
Duke University Medical Center, Durham, NC
*Purpose: Cytomegalovirus (CMV) commonly affects thoracic solid organ transplant (SOT) recipients, and standard antiviral therapies are limited by myelosuppression, renal dysfunction, and emergence of resistance.…2020 American Transplant Congress
Experience with a BKV-Specific, Neutralizing Monoclonal Antibody (MAU868) for Treatment of Severe BK Virus Nephropathy (BKVN) after Kidney Transplant (FDA EIND #139112)
*Purpose: BK viral reactivation leading to nephropathy and allograft loss in kidney transplant recipients remains a significant challenge. No effective BKV-therapies are currently available. Management…2020 American Transplant Congress
Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients
*Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…2020 American Transplant Congress
The Effect of Undernutrition and Immunosuppression on Cytomegalovirus Specific T Cell Responses
1Pediatrics, Duke University, Durham, NC, 2Surgery, Duke University, Durham, NC
*Purpose: Cytomegalovirus (CMV) infection remains a significant issue in transplantation, especially in those who are undernourished. While undernutrition is associated with impaired T cell immunity…2019 American Transplant Congress
Early Achievement of Sustained Virological Response in Liver Transplant Recipients with Hepatitis C Reduces Risks of End Stage Renal Disease
*Purpose: Chronic kidney disease (CKD) is common after liver transplantation (LT) and result worse morbidity and mortality. Hepatitis C virus (HCV) infection is recognized as…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…2019 American Transplant Congress
De-Novo Letermovir Resistant Mutations in Cytomegalovirus-Infected Tissues of Solid Organs Transplant Recipients
*Purpose: Letermovir, cytomegalovirus (CMV) DNA-terminase complex (UL51, UL56, and UL89) inhibitor, revealed the efficient prophylactic effect against CMV infection including disease and DNAemia with low-grade…2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »